These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17573995)

  • 1. Comment on: "a simple and valid tool distinguished efficacy from effectiveness studies".
    Spigt MG; Kotz D
    J Clin Epidemiol; 2007 Jul; 60(7):753-5. PubMed ID: 17573995
    [No Abstract]   [Full Text] [Related]  

  • 2. A simple and valid tool distinguished efficacy from effectiveness studies.
    Gartlehner G; Hansen RA; Nissman D; Lohr KN; Carey TS
    J Clin Epidemiol; 2006 Oct; 59(10):1040-8. PubMed ID: 16980143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple sample size formula for analysis of covariance in randomized clinical trials.
    Borm GF; Fransen J; Lemmens WA
    J Clin Epidemiol; 2007 Dec; 60(12):1234-8. PubMed ID: 17998077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 6. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T; Mitchell C; Müller-Velten G
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741-3751.
    Bauer P; Posch M
    Stat Med; 2004 Apr; 23(8):1333-4; author reply 1334-5. PubMed ID: 15083486
    [No Abstract]   [Full Text] [Related]  

  • 8. Primer on group randomized trials.
    Beach ML
    Eff Clin Pract; 2001; 4(1):42-3. PubMed ID: 11234186
    [No Abstract]   [Full Text] [Related]  

  • 9. Open-label surgical trials for Parkinson disease: time for reconsideration.
    Alterman RL; Tagliati M; Olanow CW
    Ann Neurol; 2011 Jul; 70(1):5-8. PubMed ID: 21786295
    [No Abstract]   [Full Text] [Related]  

  • 10. Contrast-induced nephropathy: we need all the data to discern the truth.
    Barrett BJ
    Am J Kidney Dis; 2009 Oct; 54(4):587-9. PubMed ID: 19781450
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer.
    Leo F; De Pas T; Catalano G; Piperno G; Curigliano G; Solli P; Veronesi G; Petrella F; Spaggiari L
    J Natl Cancer Inst; 2007 Aug; 99(15):1210; author reply 1210-1. PubMed ID: 17652281
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials: a summary.
    Wilhelmsen L; Held P; Wedel H
    J Intern Med; 2004 Oct; 256(4):284-7. PubMed ID: 15367170
    [No Abstract]   [Full Text] [Related]  

  • 13. Methodological errors in staphylococcal equivalence study.
    Richards J; Black J; Marshall C
    Clin Infect Dis; 2005 Mar; 40(5):771-2; author reply 772-3. PubMed ID: 15714433
    [No Abstract]   [Full Text] [Related]  

  • 14. [The N-of-1 trial: the ideal study design that is underused].
    Vandenbroucke JP
    Ned Tijdschr Tandheelkd; 2007 Jun; 114(6):260-2. PubMed ID: 17695213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of the "Thorough QT Study".
    Darpo B; Sager P
    Clin Pharmacol Ther; 2008 Apr; 83(4):529; author reply 530. PubMed ID: 18043696
    [No Abstract]   [Full Text] [Related]  

  • 18. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations.
    Yazici Y; Adler NM; Yazici H
    Rheumatology (Oxford); 2008 Jul; 47(7):1054-7. PubMed ID: 18495823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say?
    Gravel J; Opatrny L; Shapiro S
    Clin Trials; 2007; 4(4):350-6. PubMed ID: 17848496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size calculation for cluster randomized cross-over trials.
    Giraudeau B; Ravaud P; Donner A
    Stat Med; 2008 Nov; 27(27):5578-85. PubMed ID: 18646266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.